Blueprint Medicines (BPMC) Stock Forecast, Price Target & Predictions
BPMC Stock Forecast
Blueprint Medicines stock forecast is as follows: an average price target of $101.50 (represents a 14.17% upside from BPMC’s last price of $88.90) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.
BPMC Price Target
The average price target for Blueprint Medicines (BPMC) is $101.50 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $147.00 to $41.00. This represents a potential 14.17% upside from BPMC's last price of $88.90.
BPMC Analyst Ratings
According to 12 Wall Street analysts, Blueprint Medicines's rating consensus is 'Buy'. The analyst rating breakdown for BPMC stock is 0 'Strong Buy' (0.00%), 7 'Buy' (58.33%), 5 'Hold' (41.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Blueprint Medicines Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 01, 2024 | Matthew Biegler | Oppenheimer | $130.00 | $102.05 | 27.39% | 46.23% |
| Jul 29, 2024 | Peter Lawson | Barclays | $105.00 | $112.19 | -6.41% | 18.11% |
| Jul 08, 2024 | Matthew Biegler | Oppenheimer | $125.00 | $116.55 | 7.25% | 40.61% |
| May 06, 2024 | Andrew Berens | Leerink Partners | $97.00 | $107.19 | -9.51% | 9.11% |
| May 03, 2024 | Christopher Raymond | Raymond James | $104.00 | $106.28 | -2.15% | 16.99% |
| May 03, 2024 | Andrew Fein | H.C. Wainwright | $135.00 | $107.00 | 26.17% | 51.86% |
| Dec 14, 2022 | - | Needham | $60.00 | $46.60 | 28.76% | -32.51% |
| Nov 02, 2022 | Andrew Fein | H.C. Wainwright | $70.00 | $46.10 | 51.84% | -21.26% |
| Sep 06, 2022 | Matthew Biegler | Oppenheimer | $90.00 | $70.66 | 27.37% | 1.24% |
| Aug 17, 2022 | Derek Archila | Wells Fargo | $41.00 | $52.77 | -22.31% | -53.88% |
The latest Blueprint Medicines stock forecast, released on Aug 01, 2024 by Matthew Biegler from Oppenheimer, set a price target of $130.00, which represents a 27.39% increase from the stock price at the time of the forecast ($102.05), and a 46.23% increase from BPMC last price ($88.90).
Blueprint Medicines Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 6 |
| Avg Price Target | - | $120.00 | $116.00 |
| Last Closing Price | $88.90 | $88.90 | $88.90 |
| Upside/Downside | -100.00% | 34.98% | 30.48% |
In the current month, the average price target of Blueprint Medicines stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Blueprint Medicines's last price of $88.90. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 01, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jul 29, 2024 | Stephens | Buy | Buy | Hold |
| Jul 29, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Jul 12, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Jul 07, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jun 28, 2024 | Stephens | Underperform | Underperform | Hold |
| Jun 28, 2024 | Wedbush | Market Outperform | Market Outperform | Hold |
| Jun 07, 2024 | Wedbush | Market Outperform | Market Outperform | Hold |
| Jun 07, 2024 | Stephens | Underperform | Underperform | Hold |
| May 14, 2024 | Stephens | Underperform | Underperform | Hold |
Blueprint Medicines's last stock rating was published by Oppenheimer on Aug 01, 2024. The company gave BPMC a "Outperform" rating, the same as its previous rate.
Blueprint Medicines Financial Forecast
Blueprint Medicines Revenue Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $56.57M | $57.57M | $63.29M | $38.78M | $65.98M | - | $62.73M | $107.02M | $24.19M | $27.30M | $21.58M | $34.11M | $745.12M | $8.34M | $6.17M | $51.53M | $9.14M | $5.11M |
| Avg Forecast | $287.19M | $287.19M | $287.19M | $180.59M | $170.45M | $157.86M | $144.48M | $136.03M | $126.82M | $104.02M | $80.89M | $67.12M | $50.66M | $45.60M | $41.85M | $34.10M | $43.51M | $37.28M | $40.09M | $103.65M | $42.50M | $23.21M | $17.06M | $30.75M | $627.42M | $7.17M | $5.42M | $26.00M | $2.00M | $1.98M |
| High Forecast | $329.71M | $329.71M | $329.71M | $207.33M | $195.69M | $181.24M | $165.87M | $156.17M | $136.24M | $119.42M | $92.87M | $74.82M | $58.30M | $52.36M | $48.04M | $39.15M | $49.95M | $37.28M | $43.85M | $113.37M | $46.48M | $25.38M | $18.66M | $33.64M | $686.24M | $7.84M | $5.92M | $28.44M | $2.18M | $2.16M |
| Low Forecast | $267.93M | $267.93M | $267.93M | $168.48M | $159.02M | $147.28M | $134.79M | $126.91M | $116.12M | $97.04M | $75.47M | $61.16M | $42.74M | $42.55M | $39.04M | $31.81M | $40.59M | $37.28M | $37.33M | $96.51M | $39.57M | $21.61M | $15.88M | $28.64M | $584.19M | $6.68M | $5.04M | $24.21M | $1.86M | $1.84M |
| # Analysts | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 9 | 10 | 16 | 8 | 9 | 12 | 7 | 7 | 9 | 14 | 8 | 8 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.12% | 1.26% | 1.51% | 1.14% | 1.52% | - | 1.56% | 1.03% | 0.57% | 1.18% | 1.26% | 1.11% | 1.19% | 1.16% | 1.14% | 1.98% | 4.58% | 2.58% |
Blueprint Medicines's average Quarter revenue forecast for Dec 23 based on 10 analysts is $67.12M, with a low forecast of $61.16M, and a high forecast of $74.82M. BPMC's average Quarter revenue forecast represents a 18.66% increase compared to the company's last Quarter revenue of $56.57M (Sep 23).
Blueprint Medicines EBITDA Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 9 | 10 | 16 | 8 | 9 | 12 | 7 | 7 | 9 | 14 | 8 | 8 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-128.98M | $-127.98M | $-123.22M | $-149.80M | $-122.66M | - | $-104.18M | $-314.39M | $-115.45M | $-106.66M | $-98.11M | $-85.42M | $636.00M | $-121.81M | $-109.38M | $-68.41M | $-91.66M | $-97.17M |
| Avg Forecast | $-207.41M | $-207.41M | $-207.41M | $-130.43M | $-123.10M | $-114.01M | $-104.34M | $-98.24M | $-91.59M | $-75.13M | $-149.79M | $-48.48M | $-36.59M | $-32.94M | $-136.18M | $-24.63M | $-98.17M | $-26.93M | $-107.65M | $-190.41M | $-89.24M | $-101.24M | $-105.98M | $-90.17M | $387.86M | $-113.84M | $-107.81M | $-82.17M | $-102.18M | $-90.56M |
| High Forecast | $-193.50M | $-193.50M | $-193.50M | $-121.68M | $-114.85M | $-106.37M | $-97.35M | $-91.65M | $-83.86M | $-70.09M | $-119.84M | $-44.17M | $-30.87M | $-30.73M | $-108.94M | $-22.98M | $-78.53M | $-26.93M | $-86.12M | $-152.32M | $-71.39M | $-80.99M | $-84.78M | $-72.14M | $465.43M | $-91.07M | $-86.25M | $-65.73M | $-81.74M | $-72.44M |
| Low Forecast | $-238.12M | $-238.12M | $-238.12M | $-149.74M | $-141.33M | $-130.89M | $-119.79M | $-112.79M | $-98.39M | $-86.25M | $-179.75M | $-54.04M | $-42.10M | $-37.81M | $-163.41M | $-28.27M | $-117.80M | $-26.93M | $-129.18M | $-228.49M | $-107.09M | $-121.48M | $-127.17M | $-108.20M | $310.29M | $-136.60M | $-129.37M | $-98.60M | $-122.61M | $-108.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 3.53% | 3.89% | 0.90% | 6.08% | 1.25% | - | 0.97% | 1.65% | 1.29% | 1.05% | 0.93% | 0.95% | 1.64% | 1.07% | 1.01% | 0.83% | 0.90% | 1.07% |
7 analysts predict BPMC's average Quarter EBITDA for Dec 20 to be $-90.17M, with a high of $-72.14M and a low of $-108.20M. This is -114.18% lower than Blueprint Medicines's previous annual EBITDA (Sep 20) of $636.00M.
Blueprint Medicines Net Income Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 9 | 10 | 16 | 8 | 9 | 12 | 7 | 7 | 9 | 14 | 8 | 8 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-133.71M | $-132.79M | $-129.56M | $-158.64M | $-133.16M | - | $-106.00M | $-318.69M | $-117.24M | $-108.44M | $-99.71M | $-85.67M | $633.98M | $-123.47M | $-110.95M | $-66.33M | $-94.28M | $-99.68M |
| Avg Forecast | $70.40M | $69.77M | $69.14M | $-18.05M | $-25.50M | $-35.91M | $-45.10M | $-54.07M | $-61.39M | $-80.82M | $-153.05M | $-128.20M | $-148.79M | $-158.28M | $-139.14M | $-166.84M | $-99.69M | $-142.87M | $-109.99M | $-193.01M | $-90.63M | $-102.93M | $-107.71M | $-90.43M | $386.63M | $-115.40M | $-109.35M | $-79.68M | $-105.09M | $-92.90M |
| High Forecast | $83.95M | $83.20M | $82.45M | $-16.47M | $-23.28M | $-32.78M | $-41.17M | $-49.36M | $-53.49M | $-73.77M | $-122.44M | $-115.63M | $-133.72M | $-144.48M | $-111.31M | $-152.29M | $-79.75M | $-142.87M | $-87.99M | $-154.41M | $-72.50M | $-82.34M | $-86.17M | $-72.34M | $463.95M | $-92.32M | $-87.48M | $-63.74M | $-84.07M | $-74.32M |
| Low Forecast | $64.26M | $63.69M | $63.11M | $-21.52M | $-30.41M | $-42.82M | $-53.78M | $-64.48M | $-75.38M | $-96.37M | $-183.66M | $-142.03M | $-168.88M | $-188.75M | $-166.96M | $-198.95M | $-119.63M | $-142.87M | $-131.99M | $-231.61M | $-108.75M | $-123.52M | $-129.25M | $-108.51M | $309.30M | $-138.48M | $-131.23M | $-95.61M | $-126.10M | $-111.48M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.90% | 0.84% | 0.93% | 0.95% | 1.34% | - | 0.96% | 1.65% | 1.29% | 1.05% | 0.93% | 0.95% | 1.64% | 1.07% | 1.01% | 0.83% | 0.90% | 1.07% |
Blueprint Medicines's average Quarter net income forecast for Dec 20 is $-90.43M, with a range of $-108.51M to $-72.34M. BPMC's average Quarter net income forecast represents a -114.26% decrease compared to the company's last Quarter net income of $633.98M (Sep 20).
Blueprint Medicines SG&A Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 9 | 10 | 16 | 8 | 9 | 12 | 7 | 7 | 9 | 14 | 8 | 8 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $70.74M | $71.93M | $70.95M | $64.02M | $57.61M | - | $57.06M | $54.20M | $49.81M | $49.29M | $42.00M | $42.54M | $37.38M | $42.17M | $35.66M | $32.27M | $25.65M | $21.92M |
| Avg Forecast | $291.74M | $291.74M | $291.74M | $183.46M | $173.16M | $160.37M | $146.77M | $138.19M | $128.83M | $105.67M | $82.18M | $68.19M | $51.46M | $46.33M | $42.51M | $34.64M | $42.35M | $37.87M | $40.73M | $32.83M | $38.50M | $23.57M | $17.33M | $31.24M | $22.79M | $7.28M | $5.50M | $26.41M | $2.03M | $2.01M |
| High Forecast | $334.94M | $334.94M | $334.94M | $210.62M | $198.79M | $184.11M | $168.50M | $158.64M | $138.40M | $121.32M | $94.34M | $76.01M | $59.22M | $53.19M | $48.81M | $39.77M | $50.82M | $37.87M | $44.54M | $39.39M | $46.20M | $25.78M | $18.95M | $34.17M | $27.35M | $7.97M | $6.02M | $28.89M | $2.22M | $2.20M |
| Low Forecast | $272.18M | $272.18M | $272.18M | $171.15M | $161.54M | $149.61M | $136.93M | $128.92M | $117.96M | $98.58M | $76.66M | $62.13M | $43.42M | $43.22M | $39.66M | $32.32M | $33.88M | $37.87M | $37.92M | $26.26M | $30.80M | $21.95M | $16.14M | $29.09M | $18.23M | $6.78M | $5.12M | $24.59M | $1.89M | $1.87M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.37% | 1.55% | 1.67% | 1.85% | 1.36% | - | 1.40% | 1.65% | 1.29% | 2.09% | 2.42% | 1.36% | 1.64% | 5.79% | 6.48% | 1.22% | 12.65% | 10.91% |
Blueprint Medicines's average Quarter SG&A projection for Dec 23 is $68.19M, based on 10 Wall Street analysts, with a range of $62.13M to $76.01M. The forecast indicates a -3.61% fall compared to BPMC last annual SG&A of $70.74M (Sep 23).
Blueprint Medicines EPS Forecast
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 8 | 13 | 6 | 9 | 10 | 16 | 8 | 9 | 12 | 7 | 7 | 9 | 14 | 8 | 8 | 7 | 7 | 8 | 7 | 10 | 9 | 6 | 11 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-2.20 | $-2.19 | $-2.15 | $-2.65 | $-2.23 | - | $-1.79 | $-5.40 | $-2.00 | $-1.86 | $-1.72 | $-1.53 | $11.49 | $-2.28 | $-2.11 | $-1.35 | $-1.93 | $-2.04 |
| Avg Forecast | $1.12 | $1.11 | $1.10 | $-0.29 | $-0.41 | $-0.57 | $-0.72 | $-0.86 | $-0.98 | $-1.29 | $-1.67 | $-2.04 | $-2.37 | $-2.52 | $-2.67 | $-2.65 | $-2.49 | $-2.24 | $-1.91 | $-0.72 | $-1.60 | $-1.85 | $-1.89 | $-1.60 | $6.87 | $-2.14 | $-2.05 | $-1.69 | $-2.17 | $-1.91 |
| High Forecast | $1.34 | $1.32 | $1.31 | $-0.26 | $-0.37 | $-0.52 | $-0.65 | $-0.79 | $-0.85 | $-1.17 | $-1.52 | $-1.84 | $-2.13 | $-2.30 | $-2.44 | $-2.42 | $-2.27 | $-2.24 | $-1.74 | $-0.65 | $-1.46 | $-1.68 | $-1.72 | $-1.45 | $7.70 | $-1.95 | $-1.86 | $-1.54 | $-1.97 | $-1.74 |
| Low Forecast | $1.02 | $1.01 | $1.00 | $-0.34 | $-0.48 | $-0.68 | $-0.86 | $-1.03 | $-1.20 | $-1.53 | $-1.99 | $-2.26 | $-2.69 | $-3.00 | $-3.18 | $-3.17 | $-2.97 | $-2.24 | $-2.14 | $-0.80 | $-1.80 | $-2.07 | $-2.13 | $-1.79 | $6.25 | $-2.40 | $-2.30 | $-1.90 | $-2.43 | $-2.14 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.93% | 0.87% | 0.81% | 1.00% | 0.90% | - | 0.94% | 7.53% | 1.25% | 1.01% | 0.91% | 0.96% | 1.67% | 1.07% | 1.03% | 0.80% | 0.89% | 1.07% |
According to 7 Wall Street analysts, Blueprint Medicines's projected average Quarter EPS for Dec 20 is $-1.60, with a low estimate of $-1.79 and a high estimate of $-1.45. This represents a -113.90% decrease compared to BPMC previous annual EPS of $11.49 (Sep 20).
Blueprint Medicines Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| MDGL | Madrigal Pharmaceuticals | $241.80 | $315.75 | 30.58% | Buy |
| PTCT | PTC Therapeutics | $33.99 | $44.33 | 30.42% | Hold |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| KRYS | Krystal Biotech | $201.58 | $191.00 | -5.25% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
BPMC Forecast FAQ
Is Blueprint Medicines a good buy?
Yes, according to 12 Wall Street analysts, Blueprint Medicines (BPMC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 58.33% of BPMC's total ratings.
What is BPMC's price target?
Blueprint Medicines (BPMC) average price target is $101.5 with a range of $41 to $147, implying a 14.17% from its last price of $88.9. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Blueprint Medicines stock go up soon?
According to Wall Street analysts' prediction for BPMC stock, the company can go up by 14.17% (from the last price of $88.9 to the average price target of $101.5), up by 65.35% based on the highest stock price target, and down by -53.88% based on the lowest stock price target.
Can Blueprint Medicines stock reach $130?
BPMC's highest twelve months analyst stock price target of $147 supports the claim that Blueprint Medicines can reach $130 in the near future.
What are Blueprint Medicines's analysts' financial forecasts?
Blueprint Medicines's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $447.76M (high $504.7M, low $415.54M), average EBITDA is $-415M (high $-365M, low $-477M), average net income is $-349M (high $-299M, low $-420M), average SG&A $454.86M (high $512.7M, low $422.13M), and average EPS is $-4.789 (high $-4.331, low $-5.746). BPMC's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $653.39M (high $750.13M, low $609.57M), average EBITDA is $-472M (high $-440M, low $-542M), average net income is $-125M (high $-114M, low $-149M), average SG&A $663.75M (high $762.02M, low $619.23M), and average EPS is $-1.982 (high $-1.809, low $-2.363).
Did the BPMC's actual financial results beat the analysts' financial forecasts?
Based on Blueprint Medicines's last annual report (Dec 2023), the company's revenue was $249.38M, beating the average analysts forecast of $205.23M by 21.51%. Apple's EBITDA was $-486M, beating the average prediction of $-254M by 91.32%. The company's net income was $-507M, missing the average estimation of $-574M by -11.74%. Apple's SG&A was $295.14M, beating the average forecast of $208.49M by 41.56%. Lastly, the company's EPS was $-8.5, missing the average prediction of $-9.593 by -11.40%. In terms of the last quarterly report (Sep 2023), Blueprint Medicines's revenue was $56.57M, beating the average analysts' forecast of $50.66M by 11.66%. The company's EBITDA was $-129M, beating the average prediction of $-36.587M by 252.53%. Blueprint Medicines's net income was $-134M, missing the average estimation of $-149M by -10.13%. The company's SG&A was $70.74M, beating the average forecast of $51.46M by 37.46%. Lastly, the company's EPS was $-2.2, missing the average prediction of $-2.367 by -7.07%